Literature DB >> 33323382

Robust p53 Stabilization Is Dispensable for Its Activation and Tumor Suppressor Function.

Ning Kon1, Michael Churchill2, Huan Li1, Siddhartha Mukherjee2, James J Manfredi3, Wei Gu4.   

Abstract

p53 is a short-lived protein with low basal levels under normal homeostasis conditions. However, upon DNA damage, levels of p53 dramatically increase for its activation. Although robust stabilization of p53 serves as a "trademark" for DNA damage responses, the requirement for such dramatic protein stabilization in tumor suppression has not been well addressed. Here we generated a mutant p53KQ mouse where all the C-terminal domain lysine residues were mutated to glutamines (K to Q mutations at K367, K369, K370, K378, K379, K383, and K384) to mimic constitutive acetylation of the p53 C-terminus. Because of p53 activation, p53KQ/KQ mice were perinatal lethal, yet this lethality was averted in p53KQ/- mice, which displayed normal postnatal development. Nevertheless, p53KQ/- mice died prematurely due to anemia and hematopoiesis failure. Further analyses indicated that expression of the acetylation-mimicking p53 mutant in vivo induces activation of p53 targets in various tissues without obviously increasing p53 levels. In the well-established pancreatic ductal adenocarcinoma (PDAC) mouse model, expression of the acetylation-mimicking p53-mutant protein effectively suppressed K-Ras-induced PDAC development in the absence of robust p53 stabilization. Together, our results provide proof-of-principle evidence that p53-mediated transcriptional function and tumor suppression can be achieved independently of its robust stabilization and reveal an alternative approach to activate p53 function for therapeutic purposes. SIGNIFICANCE: Although robust p53 stabilization is critical for acute p53 responses such as DNA damage, this study underscores the important role of low basal p53 protein levels in p53 activation and tumor suppression. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33323382      PMCID: PMC8026563          DOI: 10.1158/0008-5472.CAN-20-1804

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  26 in total

1.  Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain.

Authors:  W Gu; R G Roeder
Journal:  Cell       Date:  1997-08-22       Impact factor: 41.582

Review 2.  Deconstructing networks of p53-mediated tumor suppression in vivo.

Authors:  Alyssa M Kaiser; Laura D Attardi
Journal:  Cell Death Differ       Date:  2017-11-03       Impact factor: 15.828

3.  The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells.

Authors:  Angelo Cicalese; Giuseppina Bonizzi; Cristina E Pasi; Mario Faretta; Simona Ronzoni; Barbara Giulini; Cathrin Brisken; Saverio Minucci; Pier Paolo Di Fiore; Pier Giuseppe Pelicci
Journal:  Cell       Date:  2009-09-18       Impact factor: 41.582

4.  Mutant mice lacking the p53 C-terminal domain model telomere syndromes.

Authors:  Iva Simeonova; Sara Jaber; Irena Draskovic; Boris Bardot; Ming Fang; Rachida Bouarich-Bourimi; Vincent Lejour; Laure Charbonnier; Claire Soudais; Jean-Christophe Bourdon; Michel Huerre; Arturo Londono-Vallejo; Franck Toledo
Journal:  Cell Rep       Date:  2013-06-13       Impact factor: 9.423

5.  Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53.

Authors:  R Honda; H Yasuda
Journal:  EMBO J       Date:  1999-01-04       Impact factor: 11.598

Review 6.  Targeting p53-MDM2-MDMX loop for cancer therapy.

Authors:  Qi Zhang; Shelya X Zeng; Hua Lu
Journal:  Subcell Biochem       Date:  2014

7.  Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects.

Authors:  Kelly A McGowan; Jun Z Li; Christopher Y Park; Veronica Beaudry; Holly K Tabor; Amit J Sabnis; Weibin Zhang; Helmut Fuchs; Martin Hrabé de Angelis; Richard M Myers; Laura D Attardi; Gregory S Barsh
Journal:  Nat Genet       Date:  2008-07-20       Impact factor: 38.330

8.  Transient expression of the Arf tumor suppressor during male germ cell and eye development in Arf-Cre reporter mice.

Authors:  Adam Gromley; Michelle L Churchman; Frederique Zindy; Charles J Sherr
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-01       Impact factor: 11.205

9.  p53 is active in murine stem cells and alters the transcriptome in a manner that is reminiscent of mutant p53.

Authors:  H Yan; V Solozobova; P Zhang; O Armant; B Kuehl; G Brenner-Weiss; C Blattner
Journal:  Cell Death Dis       Date:  2015-02-26       Impact factor: 8.469

10.  PBRM1 acts as a p53 lysine-acetylation reader to suppress renal tumor growth.

Authors:  Weijia Cai; Liya Su; Lili Liao; Zongzhi Z Liu; Lauren Langbein; Essel Dulaimi; Joseph R Testa; Robert G Uzzo; Zhijiu Zhong; Wei Jiang; Qin Yan; Qing Zhang; Haifeng Yang
Journal:  Nat Commun       Date:  2019-12-20       Impact factor: 14.919

View more
  3 in total

Review 1.  Deciphering the acetylation code of p53 in transcription regulation and tumor suppression.

Authors:  Zhangchuan Xia; Ning Kon; Alyssa P Gu; Omid Tavana; Wei Gu
Journal:  Oncogene       Date:  2022-04-29       Impact factor: 8.756

2.  p53 activation vs. stabilization: an acetylation tale from the C-terminal tail.

Authors:  Ning Kon; Wei Gu
Journal:  Oncoscience       Date:  2021-05-07

3.  Mechanistic insights into p53-regulated cytotoxicity of combined entinostat and irinotecan against colorectal cancer cells.

Authors:  Christian Marx; Jürgen Sonnemann; Mandy Beyer; Oliver D K Maddocks; Sergio Lilla; Irene Hauzenberger; Andrea Piée-Staffa; Kanstantsin Siniuk; Suneetha Nunna; Lisa Marx-Blümel; Martin Westermann; Tobias Wagner; Felix B Meyer; René Thierbach; Christina S Mullins; Said Kdimati; Michael Linnebacher; Francesco Neri; Thorsten Heinzel; Zhao-Qi Wang; Oliver H Krämer
Journal:  Mol Oncol       Date:  2021-07-29       Impact factor: 6.603

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.